

**THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS**  
**WITH ANTI-ERBB2 ANTIBODIES**

**ABSTRACT OF THE DISCLOSURE**

The present application describes treatment of non-malignant indications, such as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodies (*e.g.* rhuMAb 2C4).